Lexicon Pharmaceuticals posts Q2 net loss

• SONATA-HCM trial costs - Higher external research expenses for the ongoing Phase 3 SONATA-HCM trial drove up research and development costs.
• Higher SG&A costs - Selling, general and administrative expenses rose due to increased professional and consulting costs.

The current average analyst rating on the shares is buy, with a breakdown of 3 strong buy or buy, 2 hold and no sell or strong sell ratings.

The average consensus recommendation for the biotechnology and medical research peer group is buy.

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.10, about 26.5% above its August 5 closing price of $2.45.

Lexicon Pharmaceuticals posted a second-quarter net loss as revenue fell sharply year over year.